BOSTON - CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company developing treatments for neurologic disorders, announced preliminary findings from its Phase 2b RewinD-LB trial for neflamapimod ...

Key Findings from RewinD-LB Trial (Blinded 16-Week Portion) No discernible differences between neflamapimod 40mg dosed three times daily (TID) and placebo treatment groups during the 16-week ...

The study investigates neflamapimod as a treatment for dementia with Lewy bodies (DLB) and initial results were previously shared on December 10, 2024. The oral presentation will be led by Dr ...

CervoMed (CRVO) is climbing 3% after Boral Capital upgraded the shares to Buy from Hold. The investment bank placed a $10 ...

The initial topline results for the Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB) were previously disclosed on December 10, 2024 and are available here. Details of the ILBDC ...

These data will play an important role in our evaluation of the next steps in the development of neflamapimod.” The data set from the double-blind phase of the RewinD-LB trial presented today at ...

"After extensive analysis of the clinical and safety data sets and the drug product administered to participants during the double-blind phase of the study, we continue to believe neflamapimod may ...

BOSTON, Jan. 31, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (“CervoMed” or the “Company”), a clinical-stage company focused on developing treatments for age-related neurologic disorders, ...